Chromadex (NASDAQ:CDXC) posted its earnings results on Thursday. The company reported ($0.17) EPS for the quarter, meeting the Zacks’ consensus estimate of ($0.17), Yahoo Finance reports. Chromadex had a negative return on equity of 69.71% and a negative net margin of 48.68%. The company had revenue of $7.53 million for the quarter, compared to the consensus estimate of $7.50 million.
Shares of Chromadex (NASDAQ:CDXC) opened at $4.83 on Friday. Chromadex has a one year low of $2.26 and a one year high of $7.24. The company has a debt-to-equity ratio of 0.01, a quick ratio of 4.12 and a current ratio of 5.03.
CDXC has been the topic of a number of research analyst reports. HC Wainwright set a $8.00 target price on Chromadex and gave the company a “buy” rating in a research report on Friday, February 9th. BidaskClub downgraded Chromadex from a “strong-buy” rating to a “buy” rating in a research report on Friday, December 22nd. Zacks Investment Research upgraded Chromadex from a “hold” rating to a “buy” rating and set a $7.50 target price on the stock in a research report on Tuesday, November 28th. Finally, ValuEngine upgraded Chromadex from a “sell” rating to a “hold” rating in a research report on Thursday, February 8th. Two analysts have rated the stock with a sell rating, one has given a hold rating and two have assigned a buy rating to the stock. Chromadex currently has a consensus rating of “Hold” and a consensus price target of $7.50.
TRADEMARK VIOLATION NOTICE: This story was first published by Ticker Report and is the property of of Ticker Report. If you are accessing this story on another publication, it was stolen and reposted in violation of international copyright & trademark laws. The correct version of this story can be viewed at https://www.tickerreport.com/banking-finance/3253752/chromadex-cdxc-issues-earnings-results.html.
Chromadex Company Profile
Chromadex Corporation and its subsidiaries ChromaDex, Inc, ChromaDex Analytics, Inc and Spherix Consulting, Inc provide research and quality-control products and services to the natural products industry. The Company allows its business units to discover, acquire, develop and commercialize ingredient technologies that address the dietary supplement, food, beverage, skin care and pharmaceutical markets.
Receive News & Ratings for Chromadex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chromadex and related companies with MarketBeat.com's FREE daily email newsletter.